CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
1.010
-0.040 (-3.81%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.

The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.

It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine.

In addition, the company’s development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab.

It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab).

CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

CytomX Therapeutics, Inc.
CytomX Therapeutics logo
Country United States
Founded 2008
IPO Date Oct 8, 2015
Industry Biotechnology
Sector Healthcare
Employees 122
CEO Sean McCarthy

Contact Details

Address:
151 Oyster Point Boulevard, Suite 400
South San Francisco, California 94080
United States
Phone 650 515 3185
Website cytomx.com

Stock Details

Ticker Symbol CTMX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001501989
CUSIP Number 23284F105
ISIN Number US23284F1057
Employer ID 27-3521219
SIC Code 2834

Key Executives

Name Position
Dr. Hoyoung Huh M.D., Ph.D. Special Advisor to Chief Executive Officer
Dr. Sean A. McCarthy DPHIL Chairman and Chief Executive Officer
Dr. Marcia P. Belvin Ph.D. Senior Vice President and Chief Scientific Officer
Jeffrey Landau B.S., M.B.A. Senior Vice President, Head of Strategy and Chief Business Officer
Christopher W. Ogden Chief Financial Officer
Lloyd A. Rowland Jr., J.D. Senior Vice President, General Counsel, Chief Compliance Officer and Secretary
Danielle Olander-Moghadassian Senior Vice President and Chief Human Resources Officer
Leslie Robbins Senior Vice President of Intellectual Property
Dr. Yu-Waye Chu M.D. Chief Medical Officer
Dawn Benson Senior Vice President of Quality and Product Manufacturing

Latest SEC Filings

Date Type Title
Aug 19, 2024 EFFECT Notice of Effectiveness
Aug 15, 2024 UPLOAD Filing
Aug 9, 2024 S-3 Registration statement under Securities Act of 1933
Aug 8, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Jun 17, 2024 8-K Current Report
May 22, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
May 17, 2024 8-K Current Report
May 13, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
May 8, 2024 8-K Current Report